Skip to main content

Table 5 Results of the scenario 2 and one-way sensitivity analyses (24 weeks)

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Variables

Input values

Incremental costs (US $)

Incremental QALY

ICER (US $ per QALY gained)

Base case

 

466

0.0370

12,598 (₩14,198,501/QALY)

Cost ratio from Berry 2001 [27]

 

483

0.0370

13,065

  NYHA class I

0.049

   

  NYHA class II

0.049

   

  NYHA class III

0.120

   

  NYHA class IV

0.831

   

FCM price ± 15% (US $)

136-184

370-562

0.0370

10,009-15,188

Total number of FCM vials ± 1 vial

3-5

306-626

0.0370

8,282-16,915

CHF medical cost ± 25% (US $)

1,185-1,975

421-512

0.0370

11370-13,827

Effect-onset time

6th day

466

0.0370

12,598

Baseline CHF patient distribution from the expert survey

 

191

0.0370

5,165

  NYHA class II

58.3%

   

  NYHA class III

41.7%

   
  1. (US $1 = Kor ₩1,127).
  2. CHF, chronic heart failure; FMC, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association.
  3. Utility gains in scenario 2 were not changed according to variation of inputs because the utilities were directly obtained from the quality-of-life results at the follow-up periods in the FAIR-HF study.
  4. As the CHF medical cost increased, the ICER decreased.